Mitochondria-Containing Microvesicles for Scalable Mitochondria Preservation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods fail to mass-produce mitochondria effectively and preserve them for extended periods due to their susceptibility to damage outside the intracellular environment, hindering the practical application of mitochondrial preparations.

Innovation Solution

A combination of a mitochondrial generation promoting factor and an extracellular vesicle generation promoting factor is used to promote cells to produce mitochondria-containing microvesicles, which are encapsulated by small molecule RNA for protection and easier preservation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If mitochondria are isolated from cells, then mitochondrial preparations can be obtained, but they quickly become damaged and die outside the intracellular environment

Engineering Contradiction:
Improvemitochondrial preparationVSAvoidmitochondria preservation
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent uses microvesicles as intermediary carriers to transport and protect mitochondria outside the cell. The microvesicles serve as a protective medium that maintains mitochondria in a functional state outside the intracellular environment, preventing their rapid damage and death while enabling their transfer to target cells.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent embeds mitochondria inside microvesicles, creating a nested structure where the mitochondria are contained within the vesicle membrane. This nesting protects the mitochondria from external damage while allowing them to be transported and stored outside the original cell without rapid degradation.

Inventive Principle:
Principle #7Nested doll (Nesting)

2Productivity

If mitochondria are produced in large quantities, then therapeutic potential is enhanced, but current methods cannot mass-produce them

Engineering Contradiction:
Improvemitochondria production scaleVSAvoidmitochondria mass production
Core Design Contradiction:
ProductivityVSEase of manufacture

Solution Approach 1:

The patent employs stem cells that can self-renew and differentiate to continuously produce microvesicles containing mitochondria. This self-service mechanism allows for continuous, large-scale production without requiring external intervention or complex manufacturing processes, as the cells automatically generate the therapeutic products.

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent pre-processes stem cells to enhance their mitochondrial generation capacity before actual production. By using mitochondrial generation promoting factors and preparing the cells in advance, the system enables efficient mass production of mitochondria-containing microvesicles when needed.

Inventive Principle:
Principle #10Preliminary action

3Reliability

If isolated mitochondria are used for treatment, then therapeutic effects are achieved, but they are difficult to preserve for extended periods

Engineering Contradiction:
Improvetherapeutic effectVSAvoidmitochondria preservation time
Core Design Contradiction:
ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent uses microvesicles as protective intermediaries that extend the preservation time of mitochondria. The vesicle membrane acts as a protective barrier that maintains mitochondrial integrity and functionality over extended periods, enabling storage and transport without rapid degradation while preserving therapeutic activity.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical and chemical parameters of mitochondria by encapsulating them in microvesicles. This alteration in their physical state (from free-floating to encapsulated) significantly improves their stability and preservation time while maintaining their therapeutic function.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP4711448A1Method for promoting generation of microvesicles containing mitochondria and medical use thereof
Publication Date: 2026.03.18 KINGBIOS CO LTD
  • EP4711448A1 patent drawingFigure 1
  • EP4711448A1 patent drawingFigure 2
  • EP4711448A1 patent drawingFigure 3

AI summary

A method for promoting generation of a mitochondria-containing microvesicle and a pharmaceutical use thereof. Specifically, provided is a use of a combination of a mitochondrial generation promoting factor and an extracellular vesicle generation promoting factor, for use in promoting generation of the mitochondria-containing microvesicle. Also provided is a method for generating an extracellular vesicle composition: co-culturing a cell having mitochondria with the mitochondrial generation promoting factor and the extracellular vesicle generation promoting factor to obtain the extracellular vesicle composition rich in the mitochondria-containing microvesicle. Adding the above factors may promote the cell to generate the mitochondria-containing microvesicle. The collected mitochondria are encapsulated by the microvesicle, and therefore can be easily stored and transferred into the cell. Also provided are an isolated extracellular vesicle composition, a pharmaceutical composition comprising the same, and a use thereof in preparing a medicine for treating diabetes and/or renal injury.